Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vokes, E. E.
Right arrow Articles by Haraf, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vokes, E. E.
Right arrow Articles by Haraf, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 2 (January), 2003: 320-326
© 2003 American Society for Clinical Oncology

Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer

Everett E. Vokes, Kerstin Stenson, Fred R. Rosen, Merrill S. Kies, Alfred W. Rademaker, Mary Ellyn Witt, Bruce E. Brockstein, Marcy A. List, Bing Bing Fung, Louis Portugal, Bharat B. Mittal, Harold Pelzer, Ralph R. Weichselbaum, Daniel J. Haraf

From the Department of Medicine, Section of Hematology/Oncology, Department of Radiation and Cellular Oncology, Section of Otolaryngology/Head and Neck Surgery and the Cancer Research Center, University of Chicago; the Departments of Medicine, Radiation Oncology, and Otolaryngology/Head and Neck Surgery and the Cancer Research Center, Northwestern University; the Departments of Medicine, Radiation and Cellular Oncology, and Otolaryngology/Head and Neck Surgery, University of Illinois, Chicago, IL.

Address reprint requests to: Everett E. Vokes, MD, University of Chicago, 5841 S. Maryland Ave, MC 2115, Chicago, IL 60637-1470; email: evokes{at}medicine.bsd.uchicago.edu.

Purpose: The paclitaxel, fluorouracil, and hydroxyurea regimen of paclitaxel, infusional fluorouracil, hydroxyurea, and twice-daily radiation therapy (TFHX) administered every other week has resulted in 3-year survival rates of 60% of stage IV patients. Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX.

Patients and Methods: Sixty-nine patients received six weekly doses of carboplatin (AUC2) and paclitaxel (135 mg/m2) followed by five cycles of TFHX.

Results: Ninety-six percent had stage IV disease. Response to induction chemotherapy was partial response 52% and complete response (CR) 35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most common grade 3 or 4 toxicity was neutropenia (36%). Best response following completion of TFHX was CR in 83%. Toxicities of TFHX consisted of grade 3 or 4 mucositis (74% and 2%) and dermatitis (47% and 14%). At a median follow-up of 28 months, locoregional or systemic disease progression were each noted in five patients. The overall 3-year progression-free survival was 80% (95% confidence interval [CI], 71% to 90%), and the 2- and 3-year overall survival rates were 77% (95% CI, 66% to 87%) and 70% (95% CI, 59% to 82%), respectively. At 12 months, five patients were completely feeding-tube dependent.

Conclusion: Administration of carboplatin and paclitaxel before TFHX chemoradiotherapy results in high response activity and may decrease distant failure rates. Overall survival, progression, and organ preservation/functional outcome data support definitive evaluation of this approach.

Supported in part by the University of Chicago/Northwestern University Oral Cancer Center (P50 DE11921-04), University of Chicago Cancer Research Center (P30 CA14599), The Francis Lederer Foundation, The Geraldi Norton Memorial Corporation, The Robert and Valda Svendsen Memorial, and Bristol-Myers Squibb, Princeton, New York.

Presented at the Annual Meetings of the American Society of Clinical Oncology in May 2000 in New Orleans, LA, and in May 2002 in Orlando, FL.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. S. Kies, F. C. Holsinger, J. J. Lee, W. N. William Jr, B. S. Glisson, H. Y. Lin, J. S. Lewin, L. E. Ginsberg, K. A. Gillaspy, E. Massarelli, et al.
Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial
J. Clin. Oncol., January 1, 2010; 28(1): 8 - 14.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Rischin
Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials
J. Clin. Oncol., January 1, 2010; 28(1): 1 - 3.
[Full Text] [PDF]

Home page
 JCOHome page
L. K. Mell, J. J. Dignam, J. K. Salama, E. E.W. Cohen, B. N. Polite, V. Dandekar, A. D. Bhate, M. E. Witt, D. J. Haraf, B. B. Mittal, et al.
Predictors of Competing Mortality in Advanced Head and Neck Cancer
J. Clin. Oncol., January 1, 2010; 28(1): 15 - 20.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Haddad, R. B. Tishler, C. Norris, L. Goguen, T. A. Balboni, R. Costello, L. Wirth, J. Lorch, B. Andreozzi, D. Annino, et al.
Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., September 20, 2009; 27(27): 4448 - 4453.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. K. Salama, K. M. Stenson, E. O. Kistner, B. B. Mittal, A. Argiris, M. E. Witt, F. Rosen, B. E. Brockstein, E. E. W. Cohen, D. J. Haraf, et al.
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
Ann. Onc., October 1, 2008; 19(10): 1787 - 1794.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-K. Tai, M.-H. Yang, L.-W. Wang, T.-L. Tsai, P.-Y. Chu, Y.-F. Wang, J.-L. Huang, and S.-Y. Chang
Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer
Jpn. J. Clin. Oncol., August 11, 2008; (2008) hyn073v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. K. Ang
Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes
Oncologist, August 1, 2008; 13(8): 899 - 910.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
A. Langerman, E. MacCracken, K. Kasza, D. J. Haraf, E. E. Vokes, and K. M. Stenson
Aspiration in Chemoradiated Patients With Head and Neck Cancer
Arch Otolaryngol Head Neck Surg, December 1, 2007; 133(12): 1289 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. K. Salama, T. Y. Seiwert, and E. E. Vokes
Chemoradiotherapy for Locally Advanced Head and Neck Cancer
J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Kawashima, H. Fujii, R. Hayashi, M. Tahara, K. Nasu, S. Arahira, and T. Ogino
Influence of Delayed Tumor Clearance on Reliability of Complete Response Rate in Chemoradiotherapy for Head and Neck Cancer
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym072v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason
130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain
Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Quintela-Fandino, R. Hitt, P. P. Medina, S. Gamarra, L. Manso, H. Cortes-Funes, and M. Sanchez-Cespedes
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
J. Clin. Oncol., September 10, 2006; 24(26): 4333 - 4339.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, S. A. Laurie, G. S. Weinstein, W. M. Mendenhall, D. J. Adelstein, K. K. Ang, G. L. Clayman, S. G. Fisher, A. A. Forastiere, L. B. Harrison, et al.
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
J. Clin. Oncol., August 1, 2006; 24(22): 3693 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. S. C. Wong, R. A. Soo, J. J. Lu, K. S. Loh, K. S. Tan, W. S. Hsieh, T. P. Shakespeare, E. T. Chua, H. L. Lim, and B. C. Goh
Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma
Ann. Onc., July 1, 2006; 17(7): 1152 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Adelstein and M. LeBlanc
Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?
J. Clin. Oncol., June 10, 2006; 24(17): 2624 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
R. Haddad, R. Tishler, L. Wirth, C. M. Norris, L. Goguen, C. Sullivan, L. O'Donnell, Y. Li, and M. Posner
Rate of pathologic complete responses to docetaxel, Cisplatin, and Fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 678 - 681.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. R. Posner and L. J. Wirth
Cetuximab and Radiotherapy for Head and Neck Cancer
N. Engl. J. Med., February 9, 2006; 354(6): 634 - 636.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. R. Posner
Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy
Oncologist, October 1, 2005; 10(suppl_3): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
O. Laccourreye, S. Hans, M. Menard, D. Garcia, D. Brasnu, and F. C. Holsinger
Transoral Lateral Oropharyngectomy for Squamous Cell Carcinoma of the Tonsillar Region: II. An Analysis of the Incidence, Related Variables, and Consequences of Local Recurrence
Arch Otolaryngol Head Neck Surg, July 1, 2005; 131(7): 592 - 599.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Vokes
Current treatments and promising investigations in a multidisciplinary setting
Ann. Onc., January 1, 2005; 16(suppl_6): vi25 - vi30.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Huguenin, K. T. Beer, A. Allal, K. Rufibach, C. Friedli, J. B. Davis, B. Pestalozzi, S. Schmid, A. Thoni, M. Ozsahin, et al.
Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy
J. Clin. Oncol., December 1, 2004; 22(23): 4665 - 4673.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Forastiere
Is There a New Role for Induction Chemotherapy in the Treatment of Head and Neck Cancer?
J Natl Cancer Inst, November 17, 2004; 96(22): 1647 - 1649.
[Full Text] [PDF]

Home page
 JCOHome page
A. Psyrri, M. Kwong, S. DiStasio, L. Lekakis, M. Kassar, C. Sasaki, L.D. Wilson, B.G. Haffty, Y.H. Son, D.A. Ross, et al.
Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up
J. Clin. Oncol., August 1, 2004; 22(15): 3061 - 3069.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Brockstein, D. J. Haraf, A. W. Rademaker, M. S. Kies, K. M. Stenson, F. Rosen, B. B. Mittal, H. Pelzer, B. B. Fung, M.-E. Witt, et al.
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience
Ann. Onc., August 1, 2004; 15(8): 1179 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes
Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck
Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A.S. Garden, J. Harris, E.E. Vokes, A.A. Forastiere, J.A. Ridge, C. Jones, E.M. Horwitz, B.S. Glisson, L. Nabell, J.S. Cooper, et al.
Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck
J. Clin. Oncol., July 15, 2004; 22(14): 2856 - 2864.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen, M. W. Lingen, and E. E. Vokes
The Expanding Role of Systemic Therapy in Head and Neck Cancer
J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Benasso, R. Corvo, A. Ponzanelli, G. Sanguineti, I. Ricci, E. Pallestrini, A. Santelli, V. Vitale, and R. Rosso
Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck
Ann. Onc., April 1, 2004; 15(4): 646 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Argiris, B. E. Brockstein, D. J. Haraf, K. M. Stenson, B. B. Mittal, M. S. Kies, F. R. Rosen, B. Jovanovic, and E. E. Vokes
Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy
Clin. Cancer Res., March 15, 2004; 10(6): 1956 - 1962.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. S. Weinstein, E. N. Myers, S. M. Shapshay, K. T. Colvett, T. Gupta, J. Agarwal, S. G. Lashkar, M. Langer, O. Guntinas-Lichius, R. I. Haddad, et al.
Nonsurgical Treatment of Laryngeal Cancer
N. Engl. J. Med., March 4, 2004; 350(10): 1049 - 1053.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Eisbruch
Dysphagia and aspiration following chemo-irradiation of head and neck cancer: major obstacles to intensification of therapy
Ann. Onc., March 1, 2004; 15(3): 363 - 364.
[Full Text] [PDF]

Home page
 Ann OncolHome page
N. P. Nguyen, C. C. Moltz, C. Frank, P. Vos, H. J. Smith, U. Karlsson, S. Dutta, F. A. Midyett, J. Barloon, and S. Sallah
Dysphagia following chemoradiation for locally advanced head and neck cancer
Ann. Onc., March 1, 2004; 15(3): 383 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Haraf, F. R. Rosen, K. Stenson, A. Argiris, B. B. Mittal, M. E. Witt, B. E. Brockstein, M. A. List, L. Portugal, H. Pelzer, et al.
Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5936 - 5943.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. B. Lamont, D. Hayreh, K. E. Pickett, J. J. Dignam, M. A. List, K. M. Stenson, D. J. Haraf, B. E. Brockstein, S. A. Sellergren, and E. E. Vokes
Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
J Natl Cancer Inst, September 17, 2003; 95(18): 1370 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Argiris, S. M. Smith, K. Stenson, B. B. Mittal, H. J. Pelzer, M. S. Kies, D. J. Haraf, and E. E. Vokes
Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Ann. Onc., August 1, 2003; 14(8): 1306 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Argiris, D. J. Haraf, M. S. Kies, and E. E. Vokes
Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil- and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure
Oncologist, August 1, 2003; 8(4): 350 - 360.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online